Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Pediatr Infect Dis J ; 42(2): e52-e53, 2023 02 01.
Article in English | MEDLINE | ID: covidwho-2282233

ABSTRACT

The epidemiology and clinical manifestations of human metapneumovirus are not well studied in infants younger than 60 days of age. In this retrospective review of infants admitted for sepsis evaluation, we identified HMPV less frequently than other viral etiologies via nasopharyngeal multiplex polymerase chain reaction testing; in only 16 (1.9%) infants. Two infants had apneic episodes, but none had wheezing.


Subject(s)
Metapneumovirus , Paramyxoviridae Infections , Sepsis , Humans , Infant , Hospitalization/statistics & numerical data , Metapneumovirus/genetics , Metapneumovirus/isolation & purification , Nasopharynx , Paramyxoviridae Infections/diagnosis , Paramyxoviridae Infections/epidemiology , Paramyxoviridae Infections/virology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Reverse Transcriptase Polymerase Chain Reaction , Sepsis/diagnosis , Sepsis/epidemiology , Sepsis/etiology , Sepsis/virology , Age Factors
2.
Clin Lab ; 68(12)2022 Dec 01.
Article in English | MEDLINE | ID: covidwho-2121562

ABSTRACT

BACKGROUND: The incidence of respiratory viral diseases including parainfluenza virus (PIV) infection has decreased noticeably due to strict quarantine measures during the COVID-19 pandemic. However, the recent outbreak of PIV in children occurred unexpectedly and the distribution pattern showed prominent differences from before the COVID-19 pandemic. PIV is one of the major viral pathogens related to acute lower respiratory infection in young children and the elderly. Accordingly, the authors intended to identify the incidence and distribution pattern of PIV outbreaks and to contribute to public health by providing information on it. METHODS: This study was conducted retrospectively to investigate the incidence and distribution of PIV according to age group, gender, month, and season, and to analyze the co-infections from March 2020 to February 2022. The detection for respiratory microorganisms was performed through FilmArray assay. RESULTS: The overall incidence for at least one respiratory pathogen was 45.9% (665/1,450). PIV was not detected at all from March 2020 to August 2021. However, it was first detected in September 2021 and the rate in the month that followed, October, accounted for 60% (114/190) of the total PIV infections during the entire study period. It also accounted for 44.9% (190/423) of patients with respiratory pathogens from September 2021 to February 2022. It reached the highest proportion at 90.5% (114/126) in October 2021. As for the distribution according to the age groups, group 3 (58.4%) accounted for the highest percentage, followed by group 4 (21.1%). In the PIV positive cases, the overall rate of more than two respiratory pathogens was 32.6% (62/190). The most common pattern of co-infection was PIV3 with rhinovirus/enterovirus (67.7%), followed by PIV3 with adenovirus (8.1%) and PIV3 with rhinovirus/enterovirus and adenovirus (8.1%). CONCLUSIONS: The COVID-19 pandemic has brought about many changes in our daily lives. It has been confirmed that the seasonal distribution of PIV was distinctly different from before the COVID-19 pandemic. It is anticipated that this phenomenon will affect the incidence or distribution of other respiratory pathogens and viral epidemiology. Therefore, clinicians should pay attention to these changes in terms of public health.


Subject(s)
COVID-19 , Paramyxoviridae Infections , Respiratory Tract Infections , Viruses , Child , Humans , Infant , Child, Preschool , Aged , Retrospective Studies , Pandemics , COVID-19/epidemiology , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , Paramyxoviridae Infections/diagnosis , Paramyxoviridae Infections/epidemiology , Hospitals , Republic of Korea/epidemiology
3.
J Allergy Clin Immunol Pract ; 8(10): 3378-3387.e11, 2020.
Article in English | MEDLINE | ID: covidwho-773574

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic caused dramatic changes in daily routines and health care utilization and delivery patterns in the United States. Understanding the influence of these changes and associated public health interventions on asthma care is important to determine effects on patient outcomes and identify measures that will ensure optimal future health care delivery. OBJECTIVE: We sought to identify changes in pediatric asthma-related health care utilization, respiratory viral testing, and air pollution during the COVID-19 pandemic. METHODS: For the time period January 17 to May 17, 2015 to 2020, asthma-related encounters and weekly summaries of respiratory viral testing data were extracted from Children's Hospital of Philadelphia electronic health records, and pollution data for 4 criteria air pollutants were extracted from AirNow. Changes in encounter characteristics, viral testing patterns, and air pollution before and after Mar 17, 2020, the date public health interventions to limit viral transmission were enacted in Philadelphia, were assessed and compared with data from 2015 to 2019 as a historical reference. RESULTS: After March 17, 2020, in-person asthma encounters decreased by 87% (outpatient) and 84% (emergency + inpatient). Video telemedicine, which was not previously available, became the most highly used asthma encounter modality (61% of all visits), and telephone encounters increased by 19%. Concurrently, asthma-related systemic steroid prescriptions and frequency of rhinovirus test positivity decreased, although air pollution levels did not substantially change, compared with historical trends. CONCLUSIONS: The COVID-19 pandemic in Philadelphia was accompanied by changes in pediatric asthma health care delivery patterns, including reduced admissions and systemic steroid prescriptions. Reduced rhinovirus infections may have contributed to these patterns.


Subject(s)
Air Pollution/statistics & numerical data , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Child Health Services/statistics & numerical data , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Adenovirus Infections, Human/diagnosis , Adenovirus Infections, Human/epidemiology , Adolescent , Adrenal Cortex Hormones/therapeutic use , Ambulatory Care/statistics & numerical data , Asthma/physiopathology , Betacoronavirus , COVID-19 , COVID-19 Testing , Child , Child, Preschool , Clinical Laboratory Techniques , Coronaviridae Infections/diagnosis , Coronaviridae Infections/epidemiology , Coronavirus Infections/diagnosis , Coronavirus Infections/prevention & control , Emergency Service, Hospital/statistics & numerical data , Female , Hospitalization/statistics & numerical data , Hospitals, Pediatric , Humans , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Male , Nitrogen Dioxide , Ozone , Pandemics/prevention & control , Paramyxoviridae Infections/diagnosis , Paramyxoviridae Infections/epidemiology , Particulate Matter , Philadelphia/epidemiology , Picornaviridae Infections/diagnosis , Picornaviridae Infections/epidemiology , Pneumonia, Viral/diagnosis , Pneumonia, Viral/prevention & control , Respiratory Syncytial Virus Infections/diagnosis , Respiratory Syncytial Virus Infections/epidemiology , SARS-CoV-2 , Telemedicine/statistics & numerical data , Telephone , Videoconferencing
4.
Zhonghua Er Ke Za Zhi ; 58(8): 635-639, 2020 Aug 02.
Article in Chinese | MEDLINE | ID: covidwho-749115

ABSTRACT

Objective: To investigate the spectrum of pathogenic agents in pediatric patients with acute respiratory infections (ARI) during the outbreak of coronavirus infectious diseases 2019 (COVID-19). Methods: Three groups of children were enrolled into the prospective study during January 20 to February 20, 2020 from Capital Institute of Pediatrics, including children in the exposed group with ARI and epidemiological history associated with COVID-19 from whom both pharyngeal and nasopharyngeal swabs were collected, children in the ARI group without COVID-19 associated epidemiological history and children in the screening group for hospital admission, with neither COVID-19 associated epidemiological history nor ARI. Only nasopharyngeal swabs were collected in the ARI group and screening group. Each group is expected to include at least 30 cases. All specimens were tested for 2019-nCoV nucleic acid by two diagnostic kits from different manufacturers. All nasopharyngeal swabs were tested for multiple respiratory pathogens, whilst the results from the ARI group were compared with that in the correspondence periods of 2019 and 2018 used by t or χ(2) test. Results: A total of 244 children were enrolled into three groups, including 139 males and 105 females, the age was (5±4) years. The test of 2019-nCoV nucleic acid were negative in all children, and high positive rates of pathogens were detected in exposed (69.4%, 25/36) and ARI (55.3%, 73/132) groups, with the highest positive rate for mycoplasma pneumoniae (MP) (19.4%, 7/36 and 17.4%, 23/132, respectively), followed by human metapneumovirus (hMPV) (16.7%, 6/36 and 9.8%, 13/132, respectively). The positive rate (11.8%, 9/76) of pathogens in the screening group was low. In the same period of 2019, the positive rate of pathogens was 83.7% (77/92), with the highest rates for respiratory syncytial virus (RSV) A (29.3%, 27/92), followed by influenza virus (Flu) A (H1N1) (19.6%, 18/92) and adenovirus (ADV) (14.1%, 13/92), which showed significant difference with the positive rates of the three viruses in 2020 (RSV A: χ(2)=27.346, P<0.01; FluA (H1N1): χ(2)=28.083, P<0.01; ADV: χ(2)=7.848, P=0.005) . In 2018, the positive rate of pathogens was 61.0% (50/82), with the highest rate for human bocavirus (HBoV) (13.4%, 11/82) and followed by ADV (11.0%, 9/82), and significant difference was shown in the positive rate of HBoV with that in 2020 (χ(2)=6.776, P=0.009). Conclusions: The infection rate of 2019-nCoV is low among children in Beijing with no family clustering or no close contact, even with epidemiological history. The spectrum of pathogens of ARI in children during the research period is quite different from that in the previous years when the viral infections were dominant. MP is the highest positively detected one among the main pathogens during the outbreak of COVID-19 in Beijing where there is no main outbreak area.


Subject(s)
Disease Outbreaks , Metapneumovirus/isolation & purification , Mycoplasma pneumoniae/isolation & purification , Paramyxoviridae Infections/diagnosis , Respiratory Tract Infections/diagnosis , Beijing/epidemiology , Betacoronavirus , COVID-19 , Child , Child, Preschool , Coronavirus , Coronavirus Infections , Female , Humans , Infant , Influenza A Virus, H1N1 Subtype , Male , Metapneumovirus/pathogenicity , Mycoplasma pneumoniae/pathogenicity , Pandemics , Paramyxoviridae Infections/epidemiology , Pediatrics , Pneumonia, Mycoplasma/diagnosis , Pneumonia, Mycoplasma/epidemiology , Pneumonia, Viral , Prospective Studies , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/virology , SARS-CoV-2
5.
Clin Nephrol ; 94(4): 207-211, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-659342

ABSTRACT

BACKGROUND: In December 2019, the 2019 novel coronavirus disease (COVID-19) caused by SARS-CoV-2 emerged in China and now has spread to many countries. Limited data are available for hemodialysis patients with COVID-19. CASE PRESENTATION: We report a 66-year-old man with confirmed COVID-19 and parainfluenza virus infection in Wuhan. We describe the clinical characteristics, radiological findings, and treatment of the hemodialysis patient, including the patient's initial pneumonia at presentation with progression to acute respiratory distress syndrome (ARDS). DISCUSSION AND CONCLUSION: Our case underscores the possibility of SARS-CoV-2 co-infection with other pathogens in hemodialysis patients and the importance of early identification of COVID-19.


Subject(s)
Betacoronavirus , Coinfection/diagnosis , Coronavirus Infections/complications , Kidney Failure, Chronic/virology , Paramyxoviridae Infections/complications , Pneumonia, Viral/complications , Renal Dialysis , Aged , COVID-19 , China , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Male , Pandemics , Paramyxoviridae Infections/diagnosis , Paramyxoviridae Infections/therapy , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , SARS-CoV-2
6.
R I Med J (2013) ; 103(2): 75-76, 2020 Mar 19.
Article in English | MEDLINE | ID: covidwho-13511

ABSTRACT

The novel coronavirus (now called SARS-CoV-2) initially discovered in Wuhan, China, has now become a global pandemic. We describe a patient presenting to an Emergency Department in Rhode Island on March 12, 2020 with cough and shortness of breath after a trip to Jamaica. The patient underwent nasopharyngeal swab for a respiratory pathogen panel as well as SARS-CoV-2 RT-PCR. When the respiratory pathogen panel was positive for human metapneumovirus, the patient was treated and discharged. SARS-CoV-2 RT-PCR came back positive 24 hours later. Although respiratory viral co-infection is thought to be relatively uncommon in adults, this case reflects that SARS-CoV-2 testing algorithms that exclude patients who test positive for routine viral pathogens may miss SARS-CoV-2 co-infected patients.


Subject(s)
Betacoronavirus/isolation & purification , Coronavirus Infections/diagnosis , Cough/etiology , Dyspnea/etiology , Metapneumovirus/isolation & purification , Nasopharynx/virology , Paramyxoviridae Infections/diagnosis , Pneumonia, Viral/diagnosis , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Coinfection , Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Humans , Middle Aged , Pandemics , Paramyxoviridae Infections/complications , Paramyxoviridae Infections/drug therapy , Patient Isolation , Pneumonia, Viral/complications , Pneumonia, Viral/drug therapy , SARS-CoV-2 , Travel , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL